Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1994 2
1995 1
1996 3
1997 2
1998 2
1999 5
2000 9
2001 7
2002 9
2003 11
2004 6
2005 9
2006 9
2007 9
2008 10
2009 15
2010 10
2011 21
2012 19
2013 20
2014 29
2015 56
2016 80
2017 70
2018 78
2019 93
2020 83
2021 116
2022 102
2023 114
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

884 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
Ho S, Oswald E, Wong HK, Vural A, Yilmaz V, Tüzün E, Türkoğlu R, Straub T, Meinl I, Thaler F, Kümpfel T, Meinl E, Mader S. Ho S, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 26;10(2):e200083. doi: 10.1212/NXI.0000000000200083. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36702538 Free PMC article.
BACKGROUND AND OBJECTIVES: Antibodies to CD20 efficiently reduce new relapses in multiple sclerosis (MS), and ocrelizumab has been shown to be effective also in primary progressive MS. Although anti-CD20 treatments efficiently deplete B cells in blood, some B cells …
BACKGROUND AND OBJECTIVES: Antibodies to CD20 efficiently reduce new relapses in multiple sclerosis (MS), and ocrelizumab has been shown to …
Salt Intake and Immunity.
Afsar B, Kuwabara M, Ortiz A, Yerlikaya A, Siriopol D, Covic A, Rodriguez-Iturbe B, Johnson RJ, Kanbay M. Afsar B, et al. Hypertension. 2018 Jul;72(1):19-23. doi: 10.1161/HYPERTENSIONAHA.118.11128. Epub 2018 May 14. Hypertension. 2018. PMID: 29760151 Review. No abstract available.
Behcet's Disease: A Comprehensive Review on the Role of HLA-B*51, Antigen Presentation, and Inflammatory Cascade.
Khoshbakht S, Başkurt D, Vural A, Vural S. Khoshbakht S, et al. Int J Mol Sci. 2023 Nov 16;24(22):16382. doi: 10.3390/ijms242216382. Int J Mol Sci. 2023. PMID: 38003572 Free PMC article. Review.
This comprehensive review aims to explore BD's pathogenesis, focusing on established genetic factors. Studies reveal that HLA-B*51 is the primary genetic risk factor, but non-HLA genes (ERAP1, IL-10, IL23R/IL-12RB2), as well as innate immunity genes (FUT2, MICA, TLRs), als …
This comprehensive review aims to explore BD's pathogenesis, focusing on established genetic factors. Studies reveal that HLA-B*51 is …
Disposable paper-based microfluidics for fertility testing.
Sarabi MR, Yigci D, Alseed MM, Mathyk BA, Ata B, Halicigil C, Tasoglu S. Sarabi MR, et al. iScience. 2022 Aug 18;25(9):104986. doi: 10.1016/j.isci.2022.104986. eCollection 2022 Sep 16. iScience. 2022. PMID: 36105592 Free PMC article. Review.
Pilomyxoid astrocytomas: a short review.
Kulac I, Tihan T. Kulac I, et al. Brain Tumor Pathol. 2019 Apr;36(2):52-55. doi: 10.1007/s10014-019-00343-0. Epub 2019 Apr 3. Brain Tumor Pathol. 2019. PMID: 30945015 Review.
Treatment endpoints for chronic hepatitis D.
Metin O, Zeybel M, Yurdaydin C. Metin O, et al. Liver Int. 2023 Aug;43 Suppl 1:60-68. doi: 10.1111/liv.15447. Epub 2022 Oct 13. Liver Int. 2023. PMID: 36196680 Review.
In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. ...
In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatit …
New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?
Korkmaz P, Asan A, Karakeçili F, Tekin S, Demirtürk N. Korkmaz P, et al. Infect Dis Clin Microbiol. 2023 Dec 29;5(4):267-280. doi: 10.36519/idcm.2023.265. eCollection 2023 Dec. Infect Dis Clin Microbiol. 2023. PMID: 38633851 Free PMC article. Review.
Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. ...Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogs (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limi …
Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. ...Today, pegylated interferon (Peg-IFN) a …
884 results